Trial Profile
Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TOCRIVAR
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 28 Jun 2018 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned primary completion date changed from 1 Apr 2013 to 1 Mar 2017.